Back to Explorer

Guidance for the Submission of Premarket Notifications for Emission Computed Tomography Devices and Accessories (SPECT and PET) and Nuclear Tomography Systems : Guidance for Industry

FinalCenter for Devices and Radiological Health12/02/1998

Description

Comments and suggestions may be submitted at any time for Agency consideration to, Robert Phillips, Ph.D., Chief, Conventional and Therapeutic Radiological Devices Branch, HFZ-470, 9200 Corporate BLVD., Rockville, MD 20850. Comments may not be acted upon by the Agency until the document is next revised or updated. For questions regarding the use or interpretation of this guidance contact Andrew Kang, MD at (240) 276-3666 or by e-mail ats.kang@fda.hhs.gov.

Scope & Applicability

Product Classes

10
Positron Emission Tomography (PET) System

intended to detect 511 keV gamma radiation events

Nuclear Tomography System

A device intended to detect nuclear radiation in the body using a scintillation camera.

Coincidence Imaging Devices (CID)

SPECT system equipped with coincidence circuitry

Emission Computed Tomography Systems

Devices intended to detect radionuclides and produce cross-sectional images

Nuclear Tomography Systems

Devices intended to detect nuclear radiation and produce cross-sectional plane images

Single Photon Emission Tomography

Imaging system also known as SPECT

Positron Emission Tomography

PET ANDAs

Coincidence Imaging Device

Type of imaging device covered under the guidance scope

Class II device

Device classification mentioned regarding novel sterilization methods

Single Photon Emission Computed Tomography

SPECT devices intended to detect gamma radiation events and produce tomographic images

Stakeholders

2
Sponsor

Entity responsible for submitting applications under section 524B

Responsible Person

Individual authorized to determine and document eligibility; Individual who may be consulted regarding plasma dilution situations.

Regulatory Context

Attributes

3
Year 2000 Compliance

Specific compliance requirement for software in devices

Obsolete

Status of CPG Sec. 230.140 as of 7/16/2018

Moderate level of concern

In vitro diagnostic devices of this type are typically considered a moderate level of concern

Identified Hazards

Hazards

2
Device hazard analysis

Required software safety documentation

Radiation Hazard

Potential risk associated with the device to be summarized in tabular form; potential hazard associated with the device

Related CFR Sections (5)

Related Warning Letters (10)

  • CGMP/QSR/Medical Devices/Adulterated

    Envoy Medical Inc.

    2025-12-09
  • CGMP/QSR/Medical Devices/Adulterated

    Hong Qiangxing Shenzhen Electronics Limited

    2025-11-25
  • CGMP/QSR/Medical Devices/Adulterated

    Spectra Therapy, LLC

    2025-08-12
  • CGMP/QSR/Medical Devices/Adulterated

    Mectronic Medicale S.R.L.

    2025-08-05
  • CGMP/QSR/Medical Devices/Adulterated

    Aju Pharm Co., Ltd.

    2025-06-24
  • CGMP/QSR/Medical Devices/Adulterated

    Sedecal S.A.

    2025-05-27
  • CGMP/QSR/Medical Devices/Adulterated

    NeuroSync, Inc.

    2025-05-20
  • Noah Medical Corporation

    2025-04-22
  • CGMP/QSR/Medical Devices/Adulterated

    EpiCare Acquisitions, LLC

    2025-04-08
  • Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device

    Exer Labs, Inc.

    2025-03-25

See Also (8)